Enovis Corporation (NYSE: ENOV) is a Healthcare company (Medical - Devices) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Enovis Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $27.22, Enovis Corporation trades at 0.7x sales and 1.1x book value. Over the last twelve months it generated about $2.3B of revenue and a net loss of $529M. It runs a gross margin of 59.5%, an operating margin of 3.9% and a net margin of -22.9%. It shows return on equity of -35.5%, return on invested capital of 2.8% and a free cash flow yield of 4.4%. On the balance sheet: a debt-to-equity ratio of 0.90 and a current ratio of 2.15. Over the past 52 weeks the share price ranged from $16.70 to $31.67, with a beta of 1.42.
Enovis Corporation does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 12 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.